| Catalog No. | HV029026 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG4-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | T-cell immunoglobulin mucin receptor 3, HAVcr-2, TIMD-3, T-cell membrane protein 3, HAVCR2, Hepatitis A virus cellular receptor 2, CD366, TIMD3, TIM-3, TIM3, T-cell immunoglobulin and mucin domain-containing protein 3 |
|---|
| Concentration | 1.56mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | Q8TDQ0 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -277°C. |
|---|
| Alternate Names | MBG-453,CAS:2252262-24-9 |
|---|
| Background | Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
